133 related articles for article (PubMed ID: 24182700)
1. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.
De Giorgi V; Gandini S; Grazzini M; Benemei S; Marchionni N; Geppetti P
Mayo Clin Proc; 2013 Nov; 88(11):1196-203. PubMed ID: 24182700
[TBL] [Abstract][Full Text] [Related]
2. Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I.
Moser JC; Dronca RS; Markovic SN; Mansfield AS
Mayo Clin Proc; 2014 Aug; 89(8):1164-5. PubMed ID: 25092366
[No Abstract] [Full Text] [Related]
3. In reply--Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.
De Giorgi V; Gandini S; Grazzini M; Benemei S; Marchionni N; Geppetti P
Mayo Clin Proc; 2014 Aug; 89(8):1167-8. PubMed ID: 25092368
[No Abstract] [Full Text] [Related]
4. Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--II.
Hollestein LM; de Vries E
Mayo Clin Proc; 2014 Aug; 89(8):1165-7. PubMed ID: 25092367
[No Abstract] [Full Text] [Related]
5. Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.
Kim SA; Moon H; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Clin Transl Oncol; 2017 Jul; 19(7):826-833. PubMed ID: 28093700
[TBL] [Abstract][Full Text] [Related]
6. Treatment with β-blockers and reduced disease progression in patients with thick melanoma.
De Giorgi V; Grazzini M; Gandini S; Benemei S; Lotti T; Marchionni N; Geppetti P
Arch Intern Med; 2011 Apr; 171(8):779-81. PubMed ID: 21518948
[TBL] [Abstract][Full Text] [Related]
7. β-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
De Giorgi V; Grazzini M; Benemei S; Marchionni N; Geppetti P; Gandini S
Melanoma Res; 2017 Jun; 27(3):268-270. PubMed ID: 28346289
[TBL] [Abstract][Full Text] [Related]
8. Does our "flight and fight" response have a link with cancer?
Kohli M
Mayo Clin Proc; 2013 Nov; 88(11):1185-7. PubMed ID: 24182698
[No Abstract] [Full Text] [Related]
9. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
10. Combination antihypertensive therapy among patients with COPD.
Herrin MA; Feemster LC; Crothers K; Uman JE; Bryson CL; Au DH
Chest; 2013 May; 143(5):1312-1320. PubMed ID: 23287970
[TBL] [Abstract][Full Text] [Related]
11. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A Meta-Analysis.
Mukete BN; Cassidy M; Ferdinand KC; Le Jemtel TH
Am J Cardiovasc Drugs; 2015 Aug; 15(4):243-57. PubMed ID: 26055616
[TBL] [Abstract][Full Text] [Related]
13. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol: a third-generation beta-blocker for hypertension.
Cheng JW
Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
[TBL] [Abstract][Full Text] [Related]
16. Hypertension, antihypertensive agents and outcomes following renal transplantation.
Tutone VK; Mark PB; Stewart GA; Tan CC; Rodger RS; Geddes CC; Jardine AG
Clin Transplant; 2005 Apr; 19(2):181-92. PubMed ID: 15740553
[TBL] [Abstract][Full Text] [Related]
17. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.
Signorovitch JE; Samuelson TM; Ramakrishnan K; Marynchenko M; Wu EQ; Blum SI; Ramasamy A; Chen S
Curr Med Res Opin; 2012 Apr; 28(4):591-9. PubMed ID: 22352883
[TBL] [Abstract][Full Text] [Related]
18. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies.
Yap A; Lopez-Olivo MA; Dubowitz J; Pratt G; Hiller J; Gottumukkala V; Sloan E; Riedel B; Schier R
Br J Anaesth; 2018 Jul; 121(1):45-57. PubMed ID: 29935594
[TBL] [Abstract][Full Text] [Related]
19. β-Blocker-Associated Risks in Patients With Uncomplicated Hypertension Undergoing Noncardiac Surgery.
Jørgensen ME; Hlatky MA; Køber L; Sanders RD; Torp-Pedersen C; Gislason GH; Jensen PF; Andersson C
JAMA Intern Med; 2015 Dec; 175(12):1923-31. PubMed ID: 26436291
[TBL] [Abstract][Full Text] [Related]
20. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
